



MEDINEX LIMITED

**Condensed Interim Financial Statements
For the six months ended 30 September 2021**

Table of Contents

A.	Condensed interim consolidated statement of profit or loss and other comprehensive income.....	3
B.	Condensed interim statements of financial position.....	5
C.	Aggregate amount of group's borrowing and debt securities.....	7
D.	Condensed interim statements of changes in equity.....	8
E.	Condensed interim consolidated statement of cash flows.....	11
F.	Notes to the condensed interim consolidated financial statements.....	13
G.	Other information required pursuant to Appendix 7C of the Catalist Rules.....	28

A. Condensed interim consolidated statement of profit or loss and other comprehensive income

	Note	Group		Change %
		6 months ended		
		30 September 2021 S\$'000	30 September 2020 S\$'000	
Revenue	4.1	5,806	4,982	16.54
Other item of income				
Other income		1,062	586	81.23
Item of expense				
Changes in inventories		(153)	(167)	(8.38)
Inventories and consumables		(1,538)	(1,266)	21.48
Employee benefits expense		(2,048)	(1,818)	12.65
Depreciation and amortisation expenses		(299)	(351)	(14.81)
Loss allowance on trade receivables		(19)	(5)	280.00
Other expenses		(488)	(389)	25.45
Finance costs		(45)	(26)	73.08
Share of results of joint venture, net of tax		10	52	(80.77)
Profit before income tax	6	2,288	1,598	43.18
Income tax expense	7	(192)	(185)	3.78
Profit for the financial period, representing total comprehensive income for the financial period		2,096	1,413	48.34

A. Condensed interim consolidated statement of profit or loss and other comprehensive income (cont'd)

Note	Group 6 months ended		Change %	
	30 September 2021 S\$'000	30 September 2020 S\$'000		
Other comprehensive income				
Foreign currency translation differences	(6)	-	N.M.	
Other comprehensive income for the financial period, net of tax	(6)	-	N.M.	
Total comprehensive income for the financial period	2,090	1,413	47.91	
Profit attributable to:				
Owners of the Company	2,052	1,395	47.10	
Non-controlling interests	44	18	144.44	
	2,096	1,413	48.34	
Profit and total comprehensive income attributable to:				
Owners of the Company	2,046	1,395	46.67	
Non-controlling interests	44	18	144.44	
	2,090	1,413	47.91	
Earnings per share (cents)				
- Basic and diluted	9	1.56	1.06	47.17

N.M. - not meaningful

B. Condensed interim statements of financial position

	Note	Group		Company	
		30-Sep-21	31-Mar-21	30-Sep-21	31-Mar-21
		S\$'000	S\$'000	S\$'000	S\$'000
ASSETS					
Non-current assets					
Plant and equipment	12	145	135	43	51
Right-of-use assets		990	1,445	-	-
Intangible assets	11	7,052	7,098	-	-
Investment in subsidiaries		-	-	10,884	10,884
Investment in joint venture		331	321	286	286
Financial assets at fair value through profit or loss ("FVTPL")	10	4,628	4,321	4,627	4,320
Other receivables		604	589	604	589
		13,750	13,909	16,444	16,130
Current assets					
Inventories		409	562	-	-
Trade and other receivables		2,490	2,187	138	209
Contract assets		15	15	-	-
Prepayments		95	100	20	61
Fixed deposit		1,551	1,551	1,038	1,038
Cash and bank balances		7,400	5,107	1,863	1,243
		11,960	9,522	3,059	2,551
Total assets		25,710	23,431	19,503	18,681
EQUITY AND LIABILITIES					
Equity					
Share capital		14,163	14,163	14,163	14,163
Other reserve		(1,540)	(1,540)	408	408
Foreign currency translation reserve		(5)	1	-	-
Retained earnings		4,984	4,034	2,940	1,869
Equity attributable to owners of the parent		17,602	16,658	17,511	16,440
Non-controlling interests		178	269	-	-
Total equity		17,780	16,927	17,511	16,440

B. Condensed interim statements of financial position (cont'd)

	Note	Group		Company	
		30-Sep-21	31-Mar-21	30-Sep-21	31-Mar-21
		S\$'000	S\$'000	S\$'000	S\$'000
Non-current liabilities					
Deferred tax liabilities		43	43	-	-
Lease liabilities		552	910	-	-
Bank borrowings	13	4,319	2,292	-	-
Provisions		18	23		
		<u>4,932</u>	<u>3,268</u>	<u>-</u>	<u>-</u>
Current liabilities					
Trade and other payables		1,205	1,638	1,982	2,231
Lease liabilities		424	534	-	-
Contract liabilities		253	459	-	-
Bank borrowings	13	695	219	10	10
Current income tax payable		421	386	-	-
		<u>2,998</u>	<u>3,236</u>	<u>1,992</u>	<u>2,241</u>
Total liabilities		<u>7,930</u>	<u>6,504</u>	<u>1,992</u>	<u>2,241</u>
Total equity and liabilities		<u>25,710</u>	<u>23,431</u>	<u>19,503</u>	<u>18,681</u>

C. Aggregate amount of group's borrowing and debt securities

Amount repayable in one year or less, or on demand

As at 30-Sept-21			As at 31-Mar-21		
Secured		Unsecured	Secured		Unsecured
S\$'000		S\$'000	S\$'000		S\$'000
17		695	54		219

Amount repayable after one year

As at 30-Sept-21			As at 31-Mar-21		
Secured		Unsecured	Secured		Unsecured
S\$'000		S\$'000	S\$'000		S\$'000
-		4,319	28		2,292

Details of any collaterals

The Group's obligations under finance leases are secured on the plant and equipment purchased under finance lease arrangements.

D. Condensed interim statements of changes in equity

The Group		Share capital	Other reserves	Foreign currency translation reserve	Retained earnings	Equity attributable to owners of the parent	Non-controlling interests	Total equity
	Note	S\$'000	S\$'000	S\$'000	S\$'000	S\$'000	S\$'000	S\$'000
Balance at 1 April 2021		14,163	(1,540)	1	4,034	16,658	269	16,927
Profit for the financial period		-	-	-	2,052	2,052	44	2,096
Total comprehensive income for the financial period		-	-	-	2,052	2,052	44	2,096
Contributions by and distribution to owners								
Share-based payments		-	-	-	-	-	-	-
Foreign currency translation		-	-	(6)	-	(6)	-	(6)
Dividends		-	-	-	(1,102)	(1,102)	(135)	(1,237)
Total transactions with owners		-	-	(6)	(1,102)	(1,108)	(135)	(1,243)
Transactions with non-controlling interest								
Acquisition of subsidiaries		-	-	-	-	-	-	-
Dividends		-	-	-	-	-	-	-
Total transactions with non-controlling interest		-	-	-	-	-	-	-
Balance at 30 September 2021		14,163	(1,540)	(5)	4,984	17,602	178	17,780

D. Condensed interim statements of changes in equity (cont'd)

The Group		Share capital	Other reserves	Retained earnings	Equity attributable to owners of the parent	Non-controlling interests	Total equity
	Note	S\$'000	S\$'000	S\$'000	S\$'000	S\$'000	S\$'000
Balance at 1 April 2020		14,163	(1,540)	1,642	14,265	344	14,609
Profit for the financial year		-	-	1,395	1,395	18	1,413
Total comprehensive income for the financial period		-	-	1,395	1,395	18	1,413
Balance at 30 September 2020		14,163	(1,540)	3,037	15,660	362	16,022

D. Condensed interim statements of changes in equity (cont'd)

Company	Note	Share capital S\$'000	Other reserves S\$'000	Retained earnings S\$'000	Total equity S\$'000
Balance as 1 April 2021		14,163	408	1,869	16,440
Profit for the financial year		-	-	2,173	2,173
Total comprehensive income for the financial year		-	-	2,173	2,173
Contributions by and distributions to owners					
Share-based payments		-	-	-	-
Dividends		-	-	(1,102)	(1,102)
Total transactions with owners		-	-	(1,102)	(1,102)
Balance at 30 September 2021		14,163	408	2,940	17,511
Balance as 1 April 2020		14,163	408	70	14,641
Profit for the financial year		-	-	778	778
Total comprehensive income for the financial year		-	-	778	778
Contributions by and distributions to owners					
Share-based payments		-	-	-	-
Dividends		-	-	-	-
Total transactions with owners		-	-	-	-
Balance at 30 September 2020		14,163	408	848	15,419

E. Condensed interim consolidated statement of cash flows

	Note	Group	
		30 September 2021	30 September 2020
		S\$'000	S\$'000
Operating activities			
Profit before income tax		2,288	1,598
Adjustments for:			
Amortisation of intangible assets		46	49
Loss allowance on trade receivables		20	5
Gain on lease termination		(16)	-
Loss on disposal of financial asset at FVTPL		34	-
Depreciation of plant and equipment		29	16
Depreciation of right-of-use assets		225	287
Loss on plant and equipment		5	-
Gain on fair value of financial assets through profit or loss		(717)	*
Bad debt recovered		(146)	(4)
Share of results of joint venture		(10)	(52)
Dividend income from financial assets at FVTPL		(12)	-
Interest income		(15)	(57)
Interest expense		45	26
Provisions		(1)	-
Operating cash flows before working capital changes		1,775	1,868
Working capital changes:			
Inventories		153	167
Trade and other receivables		(150)	60
Prepayments		5	51
Trade and other payables		(640)	(493)
Cash generated from operations		1,143	1,653
Income tax paid		(157)	(258)
Net cash from operating activities		986	1,395

* - less than S\$1,000

E. Condensed interim consolidated statement of cash flows

	Note	Group	
		30 September 2021	30 September 2020
		S\$'000	S\$'000
Investing activities			
Interest received		-	18
Interest income from joint venture		-	55
Investment in from joint ventures		-	(25)
Dividend income from financial assets at FVTPL		12	-
Additions to intangible assets		-	(6)
Investment in financial asset at FVTPL, net		376	(1,161)
Purchase of plant and equipment		(46)	(49)
Net cash from/(used in) investing activities		342	(1,168)
Financing activities			
Advances to joint venture		(25)	-
Repayment of principal portion of lease liabilities/finance lease payables		(228)	(267)
Repayment of interest portion of lease liabilities/finance lease payables		(14)	(26)
Dividends paid to owners of the parent		(1,102)	-
Dividends paid to non-controlling interest		(135)	-
Interest paid		(25)	-
Proceeds from bank borrowings		2,500	-
Net cash from/(used in) financing activities		971	(293)
Net change in cash and cash equivalents		2,299	(66)
Cash and cash equivalents at beginning of financial period		6,658	5,265
Effect of foreign exchange rate changes on cash and cash equivalents		(6)	-
Cash and cash equivalents at end of financial period		8,951	5,199

F. Notes to the condensed interim consolidated financial statements

1. Corporate information

Medinex Limited (the “Company”) is a public limited company incorporated and domiciled in Singapore. The Company was listed on the Catalist Board of the Singapore Exchange Securities Trading Limited (the “SGX-ST”) on 7 December 2018. These condensed interim consolidated financial statements as at and for the six months ended 30 September 2021 comprise the Company and its subsidiaries (collectively, the “Group”). The primary activity of the Company is that of an investment holding company.

The principal activities of the Group are:

- (a) providing business support services;
- (b) providing medical support services; and
- (c) providing pharmaceutical services

2. Basis of Preparation

The condensed interim financial statements for the six months ended 30 September 2021 have been prepared in accordance with SFRS(I) 1-34 Interim Financial Reporting issued by the Accounting Standards Council Singapore. The condensed interim financial statements do not include all the information required for a complete set of financial statements. However, selected explanatory notes are included to explain events and transactions that are significant to an understanding of the changes in the Group’s financial position and performance of the Group since the last annual financial statements for the year ended 31 March 2021.

The accounting policies adopted are consistent with those of the previous financial year which were prepared in accordance with SFRS(I)s, except for the adoption of new and amended standards as set out in Note 2.1.

The condensed interim financial statements are presented in Singapore dollar which is the Company’s functional currency.

2.1. New and amended standards adopted by the Group

A number of amendments to Standards have become applicable for the current reporting period. The Group did not have to change its accounting policies or make retrospective adjustments as a result of adopting those standards.

2.2. Use of judgements and estimates

In preparing the condensed interim financial statements, management has made judgements, estimates and assumptions that affect the application of accounting policies and the reported amounts of assets and liabilities, income and expense. Actual results may differ from these estimates.

F. Notes to the condensed interim consolidated financial statements (cont'd)

2. Basis of Preparation (cont'd)

2.2. Use of judgements and estimates (cont'd)

The significant judgements made by management in applying the Group's accounting policies and the key sources of estimation uncertainty were the same as those that applied to the consolidated financial statements as at and for the year ended 31 March 2021.

Estimates and underlying assumptions are reviewed on an ongoing basis. Revisions to accounting estimates are recognised in the period in which the estimates are revised and in any future periods affected.

Information about critical judgements in applying accounting policies that have the most significant effect on the amounts recognised in the financial statements is included in the following notes:

- Note 10 - Classification of equity investments

Information about assumptions and estimation uncertainties that have a significant risk of resulting in a material adjustment to the carrying amounts of assets and liabilities within the next interim period are included in the following notes:

- Note 11 - impairment test of intangible assets and goodwill: key assumptions underlying recoverable amounts

3. Seasonal operations

The Group's businesses are not affected significantly by seasonal or cyclical factors during the financial period.

4. Segment and revenue information

The Group is organised into the following main business segments:

- Segment 1: Medical support services
- Segment 2: Business support services
- Segment 3: Pharmaceutical
- Segment 4: Medical services

F. Notes to the condensed interim consolidated financial statements (cont'd)

4. Segment and revenue information (cont'd)

4.1. Reportable segments

Business segment	Medical support services	Business support services	Pharmaceutical services	Medical services	Unallocated Expenses	Consolidated
1 April 2021 to 30 September 2021	(\$'000)	(\$'000)	(\$'000)	(\$'000)	(\$'000)	(\$'000)
Revenue						
External revenue	1,848	1,241	1,706	951	60	5,806
Profit from operations						
Share of results from joint ventures, net of tax	-	-	-	-	10	10
Interest income	-	-	-	-	16	16
Inventories and consumables used	10	-	1,454	227		1,691
Finance costs	30	-	3	11	1	45
Amortisation and depreciation expense	69	14	24	129	63	299
Employee benefits expense	287	26	287	413	1,035	2,048
Income tax expense	100	74	(3)	21	-	192
Reportable segment profit before income tax	1,465	1,063	(27)	167	(380)	2,288
Net profit for the financial year after tax	1,365	989	(24)	146	(380)	2,096

F. Notes to the condensed interim consolidated financial statements (cont'd)

4. Segment and revenue information (cont'd)

4.1. Reportable segments (cont'd)

Business segment	Medical support services	Business support services	Pharmaceutical services	Medical services	Unallocated Expenses	Consolidated
1 April 2020 to 30 September 2020	(\$'000)	(\$'000)	(\$'000)	(\$'000)	(\$'000)	(\$'000)
Revenue						
External revenue	1,612	1,137	1,509	721	3	4,982
Profit from operations						
Share of results from joint ventures, net of tax	-	-	-	-	(52)	(52)
Interest income	-	-	-	-	57	57
Inventories and consumables used	7	-	1,088	178	-	1,266
Finance costs	6	2	3	15	-	26
Amortisation and depreciation expense	83	61	27	126	54	351
Employee benefits expense	368	158	269	411	612	1,818
Income tax expense	59	90	32	4	-	185
Reportable segment profit before income tax	1,228	967	27	94	(718)	1,598
Net profit for the financial year after tax	1,169	877	(5)	90	(718)	1,413

F. Notes to the condensed interim consolidated financial statements (cont'd)

4. Segment and revenue information (cont'd)

4.1. Reportable segments (cont'd)

Business segment	Medical support services	Business support services	Pharmaceutical services	Medical services	Unallocated Expenses	Consolidated
1 April 2021 to 30 September 2021	(\$'000)	(\$'000)	(\$'000)	(\$'000)	(\$'000)	(\$'000)
<u>Other information:</u>						
Additions to non-current assets						
-plant and equipment	19	-	19	1	1	40
-intangible assets	-	-	-	-	-	-
-right-of-use assets	(215)	-	(215)	-	-	(430)
Segment assets	3,707	1,397	3,798	1,106	15,702	25,710
Segment liabilities	4,431	401	1,885	739	474	7,930
1 April 2020 to 30 September 2020						
<u>Other information:</u>						
Additions to non-current assets						
-plant and equipment	19	21	8	5	41	94
-intangible assets	445	-	445	-	8,312	9,202
-right-of-use assets	439	110	276	803	-	1,628
Investment in joint venture	-	-	-	-	202	202
Segment assets	2,579	1,959	1,752	1,982	11,634	19,906
Segment liabilities	957	760	596	1,238	329	3,880

F. Notes to the condensed interim consolidated financial statements (cont'd)

4. Segment and revenue information (cont'd)

4.2. Disaggregation of Revenue

Business segment	Medical support services		Business support services		Pharmaceutical services		Medical services		Total	
	1 April 2021 to 30 September 2021	1 April 2020 to 30 September 2020	1 April 2021 to 30 September 2021	1 April 2020 to 30 September 2020	1 April 2021 to 30 September 2021	1 April 2020 to 30 September 2020	1 April 2021 to 30 September 2021	1 April 2020 to 30 September 2020	1 April 2021 to 30 September 2021	1 April 2020 to 30 September 2020
	(\$'000)	(\$'000)	(\$'000)	(\$'000)	(\$'000)	(\$'000)	(\$'000)	(\$'000)	(\$'000)	(\$'000)
<u>Type of good or services</u>										
Service fee	1,848	1,611	1,241	1,137	-	-	-	-	3,089	2,748
Sale of medical and pharmaceutical products	-	-	-	-	1,706	1,509	-	-	1,706	1,509
Provision of medical services	-	-	-	-	-	-	951	720	951	720
	<u>1,848</u>	<u>1,611</u>	<u>1,241</u>	<u>1,137</u>	<u>1,706</u>	<u>1,509</u>	<u>951</u>	<u>720</u>	<u>5,746</u>	<u>4,977</u>
<u>Timing of transfer of goods and services</u>										
Point in time	1,788	1,556	1,165	1,095	1,706	1,509	951	720	5,610	4,880
Over time	60	55	76	42	-	-	-	-	136	97
	<u>1,848</u>	<u>1,611</u>	<u>1,241</u>	<u>1,137</u>	<u>1,706</u>	<u>1,509</u>	<u>951</u>	<u>720</u>	<u>5,746</u>	<u>4,977</u>

F. Notes to the condensed interim consolidated financial statements (cont'd)

5. Financial assets and financial liabilities

Set out below is an overview of the financial assets and financial liabilities of the Group as at 30 September 2021 and 31 March 2021:

	Group		Company	
	30-Sep-21 S\$'000	31-Mar-21 S\$'000	30-Sep-21 S\$'000	31-Mar-21 S\$'000
<u>Financial assets</u>				
Trade and other receivables	2,490	2,187	138	209
Cash and bank balances	7,400	5,107	1,863	1,243
Fixed Deposit	1,551	1,551	1,038	1,038
At fair value through profit or loss	4,628	4,321	4,627	4,320
<u>Financial liabilities</u>				
Trade and other payables	1,205	1,638	1,982	2,231
Lease liabilities	976	1,444	-	-
Bank borrowings	5,014	2,511	10	10

F. Notes to the condensed interim consolidated financial statements (cont'd)

6. Profit before taxation

6.1. Significant items

	30-Sep-21 (6 months) S\$'000	30-Sep-20 (6 months) S\$'000
Profit for the financial period/year is stated after charging the following:		
Fair value (gain)/loss on financial asset at fair value through profit or loss ("FVTPL")	(717)	*
Rental income	(3)	(18)
Government grant	(165)	(488)
Interest income	(15)	(57)
Loss allowance on trade receivables	20	5
Amortisation of intangible assets	46	49
Depreciation of plant and equipment	29	16
Depreciation of right-of-use assets	225	287
Cost of service	76	61
Platform fees	56	72
Professional fees	-	40

F. Notes to the condensed interim consolidated financial statements (cont'd)

7. Taxation

The Group calculates the period income tax expense using the tax rate that would be applicable to the expected total annual earnings. The major components of income tax expense in the condensed interim consolidated statement of profit or loss are:

	Period from 1 April 2021 to 30 Sep 2021 S\$'000	Period from 1 April 2020 to 30 Sep 2020 S\$'000
Current income tax		
- current financial period	192	192
Deferred tax		
- current financial period	-	(7)
Total income tax expense recognised in profit or loss	<u>192</u>	<u>185</u>

8. Dividends

	Group	
	Period from 1 April 2021 to 30 September 2021 S\$'000	Period from 1 April 2020 to 30 September 2020 S\$'000
Final tax exempt dividend of \$0.0084 per ordinary share for the financial year ended 31 March 2021	1,102	-

F. Notes to the condensed interim consolidated financial statements (cont'd)

9. Earnings Per Share

The calculation for earnings per share is based on:

	Group Half Year Ended	
	30-Sept-21 (Unaudited) S\$'000	30-Sept-20 (Unaudited) S\$'000
Profit attributable to owners of the parent (\$)	<u>2,052,000</u>	<u>1,395,000</u>
Weighted-average number of ordinary shares used in issue during the financial year/period applicable to earnings per share	<u>131,207,540</u>	<u>131,207,540</u>
<i>Earnings per share (in cents)</i>		
- Basic and diluted	<u>1.56</u>	<u>1.06</u>

The calculations of basic and diluted earnings per share are based on profit attributable to owners of the parent divided by the weighted average number of ordinary shares outstanding during the financial year/period.

The Group did not have any dilutive potential ordinary shares as at 30 September 2021 and 30 September 2020.

10. Net Asset Value

	Group		Company	
Net asset value ("NAV")	30-Sep-21 (Unaudited)	31-Mar-21 (Audited)	30-Sep-21 (Unaudited)	31-Mar-20 (Audited)
NAV (S\$) ⁽¹⁾	17,601,000	16,658,000	17,510,000	16,440,000
Number of ordinary shares in issue	131,207,540	131,207,540	131,207,540	131,207,540
NAV per ordinary share (S\$ cents)	13.41	12.70	13.35	12.53

F. Notes to the condensed interim consolidated financial statements (cont'd)

11. Financial assets at fair value through profit and loss

Financial assets at fair value through profit and loss comprise the following:

	Group and Company	
	30 Sep 2021	31 Mar 2021
	S\$'000	S\$'000
Beginning of financial period/year	4,321	887
Fair value gain	717	1,281
(Disposal)/Addition	(376)	2,148
(Loss)/Gain on disposal	(34)	5
End of financial period/year	<u>4,628</u>	<u>4,321</u>

The instruments are all mandatorily measured at fair value through profit or loss.

11.1. Fair value measurement

The Group classifies financial assets measured at fair value using a fair value hierarchy which reflects the significance of the inputs used in making the measurements. The fair value hierarchy has the following levels:

- Quoted prices (unadjusted) in active markets for identical assets or liabilities (Level 1);
- Inputs other than quoted prices included within Level 1 which are observable for the asset or liability, either directly (i.e. as prices) or indirectly (i.e. derived from prices) (Level 2); and
- Inputs for the assets or liability which are not based on observable market data (unobservable inputs) (Level 3)

Fair value measurements using

	<u>Level 1</u>	<u>Level 2</u>	<u>Level 3</u>	<u>Total</u>
	S\$'000	S\$'000	S\$'000	S\$'000
Group				
2021				
<u>Financial assets</u>				
Financial assets, at FVTPL				
- Quoted equity securities	4,628	-	-	4,628
<hr/>				
2020				
<u>Financial assets</u>				
Financial assets, at FVTPL				
- Quoted equity securities	4,321	-	-	4,321
<hr/>				

F. Notes to the condensed interim consolidated financial statements (cont'd)

12. Intangible assets

	Customer listing	Goodwill	Web development	Total
	S\$'000	S\$'000	S\$'000	S\$'000
Group				
Cost	430	6,844	6	7,280
Balance at 1 April 2021				
Additions	-	-	-	-
Balance at 30 September 2021	430	6,844	6	7,280
Accumulated amortisation				
Balance at 1 April 2020	181	-	1	182
Amortisation for the financial year	45	-	1	46
Balance at 30 September 2021	226	-	2	228
Net carrying amount				
Balance at 30 September 2021	204	6,844	4	7,052
Remaining useful life at end of financial year	1-5 years	Indefinite	4 years	

F. Notes to the condensed interim consolidated financial statements (cont'd)

12. Intangible assets (cont'd)

	Customer listing	Goodwill	Web development	Total
	S\$'000	S\$'000	S\$'000	S\$'000
Group				
Cost				
Balance at 1 April 2020	430	6,844	-	7,274
Additions	-	-	6	6
Balance at 31 March 2021	430	6,844	6	7,280
Accumulated amortisation				
Balance at 1 April 2020	81	-	-	81
Amortisation for the financial year	100	-	1	101
Balance at 31 March 2021	181	-	1	182
Net carrying amount				
Balance at 31 March 2021	249	6,844	5	7,098
Remaining useful life at end of financial year				
	1-5 years	Indefinite	4 years	

F. Notes to the condensed interim consolidated financial statements (cont'd)

13. Plant and equipment

During the six months ended 30 September 2021, the Group acquired assets amounting to \$45,967 (30 September 2020: \$38,199) and disposed of assets amounting to \$14,910 (30 September 2020: \$NIL)

14. Borrowings

	Group		Company	
	30 September 2021 S\$'000	31 March 2021 S\$'000	30 September 2021 S\$'000	31 March 2021 S\$'000
Non-current				
<i>Unsecured</i>				
Term loan I	2,292	2,292	-	-
Term loan II	2,027	-	-	-
	<hr/> 4,319	<hr/> -	<hr/> -	<hr/> -
Current				
<i>Unsecured</i>				
Term loan I	208	209	-	-
Term loan II	477	-	-	-
Revolving working capital line	10	10	10	10
	<hr/> 695	<hr/> 219	<hr/> 10	<hr/> 10
	<hr/> 5,014	<hr/> 2,510	<hr/> 10	<hr/> 10

Revolving working capital line is repayable on demand, unsecured and is arranged at floating rates.

Term loan is arranged at fixed rate and is repayable within over 60 months. It is supported by corporate guarantee provided by the Company. The carrying amount of the Group's non-current term loans approximate their fair values as the current lending rates for similar types of lending arrangements are not materially different from the rates obtained by the Group

F. Notes to the condensed interim consolidated financial statements (cont'd)

15. Related Party Transactions

There are no material related party transactions apart from those disclosed elsewhere in the financial statements.

16. Share Capital

	Group and Company			
	30 September 2021	31 March 2021	30 September 2021	31 March 2021
Number of ordinary shares			\$	\$
Issued and fully-paid:				
Balance at beginning and end of financial year/period	131,207,540	131,207,540	14,163,317	14,163,317

The Company did not hold any treasury shares as at 30 September 2021.

The Company's subsidiaries do not hold any shares in the Company as at 30 September 2021 and 31 March 2021

17. Subsequent events

There are no known subsequent events which have led to adjustments to this set of interim financial statements.

F. Other information required pursuant to Appendix 7C of the Catalist Rules

1. Whether the figures have been audited, or reviewed and in accordance with which auditing standard or practice.

The condensed consolidated statement of financial position of Medinex Limited and its subsidiaries as at 30 September 2021 and the related condensed consolidated profit or loss and other comprehensive income, condensed consolidated statement of changes in equity and condensed consolidated statement of cash flows for the six-month period then ended and certain explanatory notes have not been audited or reviewed.

2. A review of the performance of the group, to the extent necessary for a reasonable understanding of the group's business. It must include a discussion of the following:
 - (a) any significant factors that affected the turnover, costs, and earnings of the group for the current financial year reported on, including (where applicable) seasonal or cyclical factors; and
 - (b) any material factors that affected the cash flow, working capital, assets or liabilities of the group during the current financial year reported on

Review for the performance of the Group for the six months ended 30 September 2021 ("HY2022") as compared to the six months ended 30 September 2020 ("HY2021")

CONSOLIDATED STATEMENT OF COMPREHENSIVE INCOME

Revenue

The Group recorded an increase in revenue of approximately S\$0.82 million or approximately 16.54% for HY2022 as compared to HY2021. The growth in HY2022 was attributed to the increase in (a) pharmaceutical sale contributed by Nex Healthcare Pte. Ltd. ("Nex Healthcare") of approximately S\$0.22 million, (b) medical services provided by Sen Med Pte. Ltd. and its subsidiaries (the "Sen Med Group") of approximately S\$0.14 million, (c) secretary fee of approximately S\$0.11 million, (d) service fee of approximately S\$0.10 million, (e) professional services by Sen Med Group of approximately S\$0.09 million, (f) consultancy fee of approximately S\$0.07 million, (g) referral fees commission of approximately S\$0.06 million, and (h) disbursement fees of approximately S\$ 0.04 million, partially offset by the decrease in accounting fees of approximately S\$0.01 million.

Other items of income

Other income, comprising mainly of fixed deposits interest, government grants, fair value gain on financial asset at FVTPL, commission income and rental income, increased by approximately S\$0.48 million mainly due to the increase in (a) fair value gain on investment in financial asset at FVTPL of approximately S\$0.72 million, (b) bad debt recovered of approximately S\$0.15 million, (c) government grants of approximately S\$0.08 million, and (d) dividend income of approximately S\$0.03 million, partially offset by the decrease in (i) JSS grants of approximately S\$0.40 million, (ii) loss on disposal of financial assets at FVTPL of approximately S\$ 0.03 million, (iii) interest income from joint venture of approximately S\$0.03 million, (iv) rental fee of approximately S\$0.02 million, and (v) interest income of approximately S\$0.01 million.

Items of expenses

Inventories and consumables used and changes in inventories increased by approximately S\$0.27 million or approximately 21.50% due to the increase in demand for pharmaceutical products.

Employee benefits expense increased by S\$0.23 million, or approximately 12.65% due to additional headcounts arising from increase in revenue.

Amortisation and depreciation expenses decreased by approximately S\$0.05 million or approximately 14.81% in HY2022 as compared to HY2021 due mainly to (a) depreciation recognised

for right-of-use assets arising from the adoption of SFRS(I) 16 effective from 1 January 2019 of approximately S\$0.06 million, and slightly offset by the increase in depreciation of plant and equipment of approximately S\$0.01 million due to the increase in plant and equipment during HY2022.

Loss allowance on receivables increased by approximately S\$0.01 million or 280.00% due to higher impairment provisions, taking into consideration the COVID-19 situation.

Other expenses increased by approximately S\$0.10 million or approximately 25.45% in HY2022, mainly due to (a) the increase in rental expenses of approximately S\$0.07 million, (b) stamp duty disbursement cost of approximately S\$0.03 million, (c) entertainment cost of approximately S\$0.03 million, (d) ACRA fee disbursement cost of approximately S\$0.02 million and partially offset by lower operating expenses as a result of the decrease in (i) professional fees of approximately S\$0.04 million, and (ii) setup cost of approximately S\$0.01 million.

Finance cost increased by approximately S\$0.02 million or approximately 73.08% due mainly to bank interest payable from the bank loan of approximately S\$0.03 million which is partially offset by the decrease in interest recognised for the right-of-use assets arising from the adoption of SFRS(I) 16 effective from 1 January 2019 of approximately S\$0.01 million.

Share of results of joint venture is attributed to the investments in (i) approximately 27.8% of the issued share capital of Zenmedic Capital Pte. Ltd. ("Zenmedic") which was announced by the Company in May 2019, (ii) approximately 25% of the issued share capital of J-Connect Media Pte. Ltd. ("J-Connect") which was announced in July 2020, and (iii) 20% of the issued share capital of Healthcare Essentials Pte Ltd ("Healthcare Essentials") which was announced by the Company in December 2020. The decrease in the share of results of joint venture of approximately S\$0.04 million is due to the share of loss in J-Connect and lower share of profit of investment in Zenmedic in HY2022.

Profit before income tax

As a result of the abovementioned, profit before income tax increased by approximately S\$0.69 million or approximately 43.18%.

Income tax expense

Income tax expenses increased by approximately S\$0.01 million or approximately 3.78% due to higher taxable profits recorded in HY2022 compared to HY2021.

CONSOLIDATED STATEMENT OF FINANCIAL POSITION

The comparative performance for both the assets and liabilities are based on the Group's financial statements as at 30 September 2021 and 31 March 2021 ("FY2021").

Non-current assets

The Group's non-current assets mainly relates to plant and equipment, right-of-use assets, intangible assets, investment in joint venture, financial assets at FVTPL and other receivables.

The Group's intangible assets (which relates to customer relationships) decrease by approximately S\$0.05 million due to amortisation of customer relationship.

The Group's investment in joint venture increased by approximately S\$0.01 million due to profit from Zenmedic of approximately S\$0.01 million and the profit from Healthcare Essentials of approximately S\$0.01 million, partially offset by the loss from J-Connect of approximately S\$0.01 million.

The Group's right-of-use assets decreased by approximately S\$0.45 million due to depreciation of approximately S\$0.22 million and loss on lease termination of approximately S\$0.43 million, and offset by entering into new lease agreements of approximately S\$0.20 million.

The Group's plant and equipment increased by approximately S\$0.01 million mainly due to purchases of approximately S\$0.04 million computer equipment and offset by the disposal of office equipment of approximately S\$0.03 million.

Financial assets at FVTPL increased by approximately S\$0.31 million due to fair value gained of approximately S\$0.72 million and partially offset by the disposal of quoted investment of approximately S\$0.38 million and the loss on disposal of quoted investment of approximately S\$0.03 million.

Other receivables increased by approximately S\$0.01 million due to interest incurred on the loan provided to the Company's joint venture entity, Zenmedic. This interest is an accounting interest pursuant to SFRS(I) 109 arising from the recognition of the loan at fair value at inception.

Current assets

Inventories decreased by approximately S\$0.15 million which was in line with the increase sale of pharmaceutical products.

Trade and other receivables increased by approximately S\$0.30 million due to an increase in receivables outstanding from clients which was in line with the increase in the total revenue of the Group.

Non-current liabilities

The Group recorded a decrease in lease liabilities of approximately S\$0.36 million due to lease repayment during HY2022.

The Group's borrowings increased by approximately S\$2.03 million arising from the bank loan taken by Nex Healthcare.

The Group had a decrease in provisions due to the rental of smaller office space by Nex Healthcare.

Current liabilities

Trade and other payables decreased by approximately S\$0.43 million mainly due to decreased payables arising from the decrease in (a) trade payables in HY2022 of approximately S\$0.20 million, (b) GST payable of approximately S\$0.03 million, (c) deferred grant income of approximately S\$0.08 million, and (d) other accruals of approximately S\$0.21 million incurred in FY2021 and offset by the increase in other creditors of approximately S\$0.09 million.

The Group recorded a decrease in lease liabilities of approximately S\$0.11 million due to lease repayment during HY2022.

Contract liabilities decreased by approximately S\$0.21 million mainly due to the advanced payment received from customers of approximately S\$0.05 million and the deferred income of approximately S\$0.16 million.

The Group's borrowings increased by approximately S\$0.48 million arising from the bank loan taken by Nex Healthcare.

The increase in current income tax payables of approximately S\$0.04 million was due to higher taxable profits recorded in HY2022 compared to FY2021.

Equity

Total retained earnings increased by approximately S\$0.95 million, from approximately S\$4.03 million as at 31 March 2021 to S\$4.98 million as at 30 September 2021, mainly due to an increase in profit after tax of S\$0.95 million as at 30 September 2021, as a result of net profit incurred in HY2022.

CONSOLIDATED STATEMENT OF CASH FLOWS

The Group recorded net cash generated from operating activities of approximately S\$0.98 million in HY2022, mainly due to operating cash flow before changes in working capital of approximately S\$1.78 million, and adjusted for net working capital outflow of approximately S\$0.63 million and income tax paid of S\$0.16 million. The net working capital outflow was mainly due to the (a) decrease in trade and other payables of approximately S\$0.64 million, and (b) increase in trade and other receivables of approximately S\$0.15 million and partially offset by a decrease in inventory of approximately S\$0.15 million and the decrease in prepayments of approximately S\$0.01 million.

Net cash from investing activities of approximately S\$0.34 million in HY2022 was mainly due to sale of financial asset at FVTPL of approximately S\$0.38 million and dividend income from financial asset at FVTPL of approximately S\$0.01 million, which is partially offset by the purchase of plant and equipment of approximately S\$0.05 million.

Net cash from financing activities amounted to approximately S\$0.97 million, arising mainly from the bank borrowing amounting to approximately S\$2.5 million, which is partially offset by (a) dividend payout to shareholders of the Company and non-controlling interests of Sen Med of approximately S\$1.24 million, (b) repayment of lease liabilities of approximately S\$0.23 million, (c) repayment of interest expenses amounting to S\$0.04 million and (d) advances to joint venture of approximately S\$0.03 million.

Overall, the Group recorded a net increase in cash and cash equivalents of approximately S\$2.30 million in HY2022, mainly due to bank borrowings.

Where a forecast, or a prospect statement, has been previously disclosed to shareholders, any variance between it and the actual results

Not applicable as no forecast or prospect statement has been made or disclosed previously.

A commentary at the date of the announcement of the significant trends and competitive conditions of the industry in which the group operates and any known factors or events that may affect the group in the next reporting period and the next 12 months.

For HY2022, the Group continues to face an uncertain and challenging business environment. The prolonged pandemic has adversely affected many businesses, including our clients. During this period, Medinex has reached out to the clients who were adversely affected by the pandemic and referred them to banks to tap on the bridging loans offered to assist in the businesses' financial situation. Medinex has also initiated a voluntary one-time adjustment of fees to help ease our clients' financial distress.

Notwithstanding that the pandemic has drained many businesses of their traditional sources of revenue, it has nudged many to leverage on the digital and online channel to reach out to their potential markets. The Group has capitalised on this opportunity to set-up a marketing and call service centre to provide services which include, among others, digital marketing consultation, advertising and administration services to support our clients.

Concurrently, Medinex will continue to enhance the expansion of our principal business consultancy and support activities to facilitate regional investors in establishing their business in Singapore. Singapore has become an attractive port to many regional investors to establish their base here. It is also an opportunity for the Group to help our high net-worth individuals and their families to set up a family office in Singapore.

As a long-term strategy to reduce the overall corporate costs and expenses, the Group will continue to grow the team in Johor Bahru, Malaysia to reduce the Group's overall manpower cost while maintaining stringent internal controls and quality output.

3. Dividend

If a decision regarding dividend has been made: -

- (a) Whether an interim (final) ordinary dividend has been declared (recommended); and

Dividends in respect of the financial period from 1 April 2020 to 31 March 2021 have been declared and paid previously.

The following interim dividend will be declared on 06 December 2021 for the six (6) months period ended 31 March 2022.

Name of Dividend	Interim
Dividend Type	Ordinary
Dividend Amount per Share (in S\$ cents)	0.84 cents per ordinary share (one tier tax)
Tax Rate	Tax exempt

The distribution of the interim dividends represented approximately 53% of the Group's net profit after tax attributable to Shareholders for the financial period from 01 April 2021 to 30 September 2021.

- (b) (i) Amount per share (cents)

Please refer to paragraph 3(a).

- (ii) Previous corresponding period (cents)

Name of Dividend	Proposed Interim
Dividend Type	Ordinary
Dividend Amount per Share (in S\$ cents)	0.84 cents per ordinary share (one tier tax)
Tax Rate	Tax exempt

- (c) Whether the dividend is before tax, net of tax or tax exempt. If before tax or net of tax,

state the tax rate and the country where the dividend is derived. (if the dividend is not taxable in the hands of shareholders, this must be stated.)

Please refer to paragraph 3(a).

- (d) The date the dividend is payable.

The dividend will be paid on 6 December 2021.

- (e) The date on which Registrable Transfers received by the Company (up to 5.00pm) will be registered before entitlements to the dividend are determined.

Notice is hereby given that the Share Transfer Books and the Register of Members of the Company will be closed at 5.00 p.m. on 23 November 2021 for the purpose of determining shareholders' entitlements to the interim dividend.

Duly completed transfers of shares received by the Company's Share Registrar, Tricor Barbinder Share Registration Services (A division of Tricor Singapore Pte. Ltd.) at 80 Robinson Road, #02-00, Singapore 068898, up to 5.00 p.m. on 23 November 2021 will be registered to determine shareholders' entitlements to the Interim Dividend.

Shareholders (being depositors) whose securities accounts with The Central Depository (Pte) Limited are credited with shares as at 5.00 p.m. on 23 November 2021 will be entitled to the Interim Dividend.

4. Interested Party Transactions

The Company does not have a general mandate from shareholders for interested person transactions.

The Company confirms that there were no IPT transactions of more than S\$100,000 in HY2022.

5. Use of IPO Proceeds

The Company refers to the net cash proceeds amounting to S\$5.28 million (excluding cash listing expenses of approximately S\$1.22 million) raised from the IPO on the Catalist Board of SGX-ST on 7 December 2018.

As at the date of the announcement, the status on the use of the IPO net proceeds is as follows:

	Amount allocated (S\$'000)	Amount utilised (S\$'000)	Balance (S\$'000)
Expand our Group's business operations via acquisitions, joint ventures and/or strategic partnerships	4,000.00	3532.50 ⁽¹⁾	467.50
Working Capital	1,316.00	786.00 ⁽²⁾	530.00
Total	5,316.00	4,318.50	997.50

Notes:

- (1) Utilised for the following:-
 - (a) acquisition of Sen Med. - S\$1,732,500;
 - (b) acquisition of Ark - S\$600,000;
 - (c) acquisition of SKIC and Medinex Advisory – S\$1,200,000

- (2) Utilised for the payment of listing expenses of S\$36,000 and the provision of the convertible loan amount of S\$750,000 to Singapore Paincare Holdings Limited.

The utilisation is in accordance with the intended use as stated in the Company's offer document dated 30 November 2018.

6. Confirmation that the issuer has procured undertaking from all its directors and executive officers (in the format set out in Appendix 7H) under Rule 720(1)

The Company confirms that it has procured undertaking from all its directors and executive officers (in the format as set out in Appendix 7H) under Rule 720(1) of the SGX-ST Listing Manual Section B: Rules of Catalist ("**Catalist Rules**").

7. Confirmation by the Board pursuant to Rule 705(5) of the Catalist Rules

On behalf of the Board of Directors of the Company, we, the undersigned, hereby confirm to the best of our knowledge that nothing has come to the attention of the Board of Directors of the Company which may render the financial statements for the six-month period ended 30 September 2021 to be false or misleading in any material aspect.

BY ORDER OF THE BOARD

Jessie Low Mui Choo
Executive Director and Chief Executive Officer

Tan Lee Meng
Non-Executive Chairman

Singapore
12 November 2021

*This announcement has been prepared by the Company and reviewed by the Company's Sponsor, Novus Corporate Finance Pte. Ltd. (the "**Sponsor**"), in compliance with Rule 226(2)(b) of the SGX-ST Listing Manual Section B: Rules of Catalyst.*

This announcement has not been examined or approved by the SGX-ST and the SGX-ST assumes no responsibility for the contents of this announcement including the correctness of any of the statements or opinions made, or reports contained in this announcement.

The contact person for the Sponsor is Mr. Pong Chen Yih, Chief Operating Officer, at 7 Temasek Boulevard, #18-03B Suntec Tower 1, Singapore 038987, telephone (65) 6950 2188.